Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NGM BIOPHARMACEUTICALS INC (NGM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 SC 13G/A BlackRock Inc. reports a 4.6% stake in NGM BIOPHARMACEUTICALS INC
08/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/07/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/04/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights"
06/08/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Open Market Sale AgreementSM, between the Company and Jefferies"
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/04/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "How The Decision Was Reached"
03/29/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/29/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2023 ARS Form ARS - Annual Report to Security Holders:
03/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5.5% stake in NGM Biopharmaceuticals Inc.
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
12/20/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
10/28/2022 SC 13G EcoR1 Capital, LLC reports a 8% stake in NGM Biopharmaceuticals, Inc.
10/17/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration"
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/10/2022 SC 13D/A COLUMN GROUP L P reports a 26.5% stake in NGM BIOPHARMACEUTICALS, INC.
05/24/2022 8-K Quarterly results
05/20/2022 10-K/A Annual Report for the period ended December 31, 2021 [amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy